221 related articles for article (PubMed ID: 9878454)
1. The role of complement and gp120-specific antibodies in virus lysis and CD4+ T cell depletion in HIV-1-infected patients.
Gerencer M; Burek V; Crowe BA; Barrett NP; Dorner F
Microb Pathog; 1998 Nov; 25(5):253-66. PubMed ID: 9878454
[TBL] [Abstract][Full Text] [Related]
2. Complement activation by recombinant HIV-1 glycoprotein gp120.
Süsal C; Kirschfink M; Kröpelin M; Daniel V; Opelz G
J Immunol; 1994 Jun; 152(12):6028-34. PubMed ID: 7911492
[TBL] [Abstract][Full Text] [Related]
3. Specific adaptive humoral response against a gp41 motif inhibits CD4 T-cell sensitivity to NK lysis during HIV-1 infection.
Vieillard V; Costagliola D; Simon A; Debré P;
AIDS; 2006 Sep; 20(14):1795-804. PubMed ID: 16954720
[TBL] [Abstract][Full Text] [Related]
4. Binding of HIV-1 virions or gp120-anti-gp120 immune complexes to HIV-1-infected quiescent peripheral blood mononuclear cells reveals latent infection.
Briant L; Coudronnière N; Robert-Hebmann V; Benkirane M; Devaux C
J Immunol; 1996 May; 156(10):3994-4004. PubMed ID: 8621941
[TBL] [Abstract][Full Text] [Related]
5. Are blockers of gp120/CD4 interaction effective inhibitors of HIV-1 immunopathogenesis?
Herbeuval JP; Shearer GM
AIDS Rev; 2006; 8(1):3-8. PubMed ID: 16736946
[TBL] [Abstract][Full Text] [Related]
6. Recombinant gp120 specifically enhances tumor necrosis factor-alpha production and Ig secretion in B lymphocytes from HIV-infected individuals but not from seronegative donors.
Rieckmann P; Poli G; Fox CH; Kehrl JH; Fauci AS
J Immunol; 1991 Nov; 147(9):2922-7. PubMed ID: 1918999
[TBL] [Abstract][Full Text] [Related]
7. Plasma levels of viro-immunological markers in HIV-infected and non-infected Ethiopians: correlation with cell surface activation markers.
Messele T; Brouwer M; Girma M; Fontanet AL; Miedema F; Hamann D; Rinke de Wit TF
Clin Immunol; 2001 Feb; 98(2):212-9. PubMed ID: 11161977
[TBL] [Abstract][Full Text] [Related]
8. Deletion of T lymphocytes in human CD4 transgenic mice induced by HIV-gp120 and gp120-specific antibodies from AIDS patients.
Wang ZQ; Orlikowsky T; Dudhane A; Mittler R; Blum M; Lacy E; Riethmüller G; Hoffmann MK
Eur J Immunol; 1994 Jul; 24(7):1553-7. PubMed ID: 7913036
[TBL] [Abstract][Full Text] [Related]
9. CD4-imitating human antibodies in HIV infection and anti-idiotypic vaccination.
Deckert PM; Ballmaier M; Lang S; Deicher H; Schedel I
J Immunol; 1996 Jan; 156(2):826-33. PubMed ID: 8543839
[TBL] [Abstract][Full Text] [Related]
10. CD4 epitope masking by gp120/anti-gp120 antibody complexes. A potential mechanism for CD4+ cell function down-regulation in AIDS patients.
Amadori A; De Silvestro G; Zamarchi R; Veronese ML; Mazza MR; Schiavo G; Panozzo M; De Rossi A; Ometto L; Mous J
J Immunol; 1992 May; 148(9):2709-16. PubMed ID: 1374095
[TBL] [Abstract][Full Text] [Related]
11. Shared antigenic epitopes on the V3 loop of HIV-1 gp120 and proteins on activated human T cells.
Trujillo JR; Rogers RA; Brain JD
Virology; 1998 Jun; 246(1):53-62. PubMed ID: 9656993
[TBL] [Abstract][Full Text] [Related]
12. Complement-activating antibodies in sera from infected individuals and vaccinated volunteers that target human immunodeficiency virus type 1 to complement receptor type 1 (CR1, CD35).
Zhou J; Montefiori DC
Virology; 1996 Dec; 226(1):13-21. PubMed ID: 8941318
[TBL] [Abstract][Full Text] [Related]
13. Anticardiolipin antibodies in HIV infection are independently associated with antibodies to the membrane proximal external region of gp41 and with cell-associated HIV DNA and immune activation.
Martinez V; Diemert MC; Braibant M; Potard V; Charuel JL; Barin F; Costagliola D; Caumes E; Clauvel JP; Autran B; Musset L;
Clin Infect Dis; 2009 Jan; 48(1):123-32. PubMed ID: 19035778
[TBL] [Abstract][Full Text] [Related]
14. Dexamethasone inhibits CD4 T cell deletion mediated by macrophages from human immunodeficiency virus-infected persons.
Orlikowsky TW; Wang ZQ; Dudhane A; Dannecker GE; Niethammer D; Wormser GP; Hoffmann MK; Horowitz HW
J Infect Dis; 2001 Nov; 184(10):1328-30. PubMed ID: 11679924
[TBL] [Abstract][Full Text] [Related]
15. Concomitant killing in vitro of both gp120-coated CD4+ peripheral T lymphocytes and natural killer cells in the antibody-dependent cellular cytotoxicity (ADCC) system.
Jewett A; Cavalcanti M; Giorgi J; Bonavida B
J Immunol; 1997 Jun; 158(11):5492-500. PubMed ID: 9164972
[TBL] [Abstract][Full Text] [Related]
16. Naive T-cell depletion related to infection by X4 human immunodeficiency virus type 1 in poor immunological responders to highly active antiretroviral therapy.
Delobel P; Nugeyre MT; Cazabat M; Sandres-Sauné K; Pasquier C; Cuzin L; Marchou B; Massip P; Cheynier R; Barré-Sinoussi F; Izopet J; Israël N
J Virol; 2006 Oct; 80(20):10229-36. PubMed ID: 17005700
[TBL] [Abstract][Full Text] [Related]
17. Relationship of antibodies against CD4+ T cells in HIV-infected patients to markers of activation and progression: autoantibodies are closely associated with CD4 cell depletion.
Müller C; Kukel S; Bauer R
Immunology; 1993 Jun; 79(2):248-54. PubMed ID: 8102120
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of CCR5 on activated CD4 T cells in HIV-infected Indians.
Dubey S; Khalid M; Wesley C; Khan SA; Wanchu A; Jameel S
J Clin Virol; 2008 Sep; 43(1):25-31. PubMed ID: 18462992
[TBL] [Abstract][Full Text] [Related]
19. Detection of T cell CD4 epitopes in HIV-infected individuals.
Kunkl A; Valle MT; Fenoglio D; Dodi F; Morandi N; Rizzo F; Manca F
Eur J Histochem; 1994; 38 Suppl 1():41-6. PubMed ID: 8547709
[TBL] [Abstract][Full Text] [Related]
20. Human immunodeficiency virus (HIV)-specific antibody in cervicovaginal lavage specimens obtained from women infected with HIV type 1.
Williams SB; Flanigan TP; Cu-Uvin S; Mayer K; Williams P; Ettore CA; Artenstein AW; Duerr A; VanCott TC
Clin Infect Dis; 2002 Sep; 35(5):611-7. PubMed ID: 12173138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
